Short-Term Outcomes of Infants and Children Receiving Selexipag for Pulmonary Hypertension

Administration of selexipag in infants and children appears safe, and is a viable alternative to other forms of prostacyclin administration in stable patients. Selexipag may also have a role as tertiary adjunct therapy for those who do not improve on dual oral therapy.